Apellis Pharmaceuticals Inc (APLS) - Total Assets
Based on the latest financial reports, Apellis Pharmaceuticals Inc (APLS) holds total assets worth $1.08 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Apellis Pharmaceuticals Inc - Total Assets Trend (2013–2025)
This chart illustrates how Apellis Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see Apellis Pharmaceuticals Inc (APLS) market capitalisation for the company's overall valuation and market capitalisation.
Apellis Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Apellis Pharmaceuticals Inc's total assets of $1.08 Billion consist of 94.4% current assets and 5.6% non-current assets. Review Apellis Pharmaceuticals Inc total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 43.5% |
| Accounts Receivable | $366.22 Million | 34.1% |
| Inventory | $142.56 Million | 13.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Apellis Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Apellis Pharmaceuticals Inc stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Apellis Pharmaceuticals Inc's current assets represent 94.4% of total assets in 2025, a decrease from 99.8% in 2013.
- Cash Position: Cash and equivalents constituted 43.5% of total assets in 2025, down from 91.5% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 34.1% of total assets.
Apellis Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Apellis Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Apellis Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.63 | 4.08 | 4.15 |
| Quick Ratio | 3.16 | 3.62 | 4.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $744.57 Million | $549.34 Million | $497.34 Million |
Apellis Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Apellis Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.66 |
| Latest Market Cap to Assets Ratio | 0.38 |
| Asset Growth Rate (YoY) | 21.5% |
| Total Assets | $1.08 Billion |
| Market Capitalization | $412.48 Million USD |
Valuation Analysis
Below Book Valuation: The market values Apellis Pharmaceuticals Inc's assets below their book value (0.38x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Apellis Pharmaceuticals Inc's assets grew by 21.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Apellis Pharmaceuticals Inc (2013–2025)
The table below shows the annual total assets of Apellis Pharmaceuticals Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.08 Billion | +21.49% |
| 2024-12-31 | $885.05 Million | +12.21% |
| 2023-12-31 | $788.73 Million | +3.75% |
| 2022-12-31 | $760.22 Million | -13.78% |
| 2021-12-31 | $881.76 Million | -8.20% |
| 2020-12-31 | $960.57 Million | +146.78% |
| 2019-12-31 | $389.24 Million | +91.24% |
| 2018-12-31 | $203.53 Million | +11.75% |
| 2017-12-31 | $182.13 Million | +563.91% |
| 2016-12-31 | $27.43 Million | -28.14% |
| 2015-12-31 | $38.18 Million | +166.86% |
| 2014-12-31 | $14.31 Million | +175.15% |
| 2013-12-31 | $5.20 Million | -- |
About Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy… Read more